$33.22
0.37% yesterday
Nasdaq, Oct 30, 09:01 pm CET
ISIN
US98419J2069
Symbol
XOMA

XOMA Corporation Stock price

$33.22
-5.32 13.80% 1M
+9.18 38.19% 6M
+6.94 26.41% YTD
+3.36 11.25% 1Y
+16.66 100.60% 3Y
+8.41 33.90% 5Y
+8.82 36.15% 10Y
-476.78 93.49% 20Y
Nasdaq, Closing price Thu, Oct 30 2025
-0.13 0.37%
ISIN
US98419J2069
Symbol
XOMA
Industry

Key metrics

Basic
Market capitalization
$400.9m
Enterprise Value
$430.9m
Net debt
$30.0m
Cash
$83.9m
Shares outstanding
12.1m
Valuation (TTM | estimate)
P/E
negative | 60.3
P/S
8.9 | 7.5
EV/Sales
9.6 | 8.0
EV/FCF
negative
P/B
4.3
Financial Health
Equity Ratio
37.0%
Return on Equity
-23.6%
ROCE
4.7%
ROIC
-
Debt/Equity
1.2
Financials (TTM | estimate)
Revenue
$45.0m | $53.8m
EBITDA
$11.0m | $27.0m
EBIT
$9.5m | $17.9m
Net Income
$-17.7m | $6.7m
Free Cash Flow
$-23.0m
Growth (TTM | estimate)
Revenue
168.7% | 88.9%
EBITDA
148.6% | 611.9%
EBIT
141.6% | 427.0%
Net Income
42.2% | 134.6%
Free Cash Flow
-178.3%
Margin (TTM | estimate)
Gross
-
EBITDA
24.4% | 50.1%
EBIT
21.2%
Net
-39.4% | 12.4%
Free Cash Flow
-51.3%
More
EPS
$-1.0
FCF per Share
$-1.9
Short interest
2.8%
Employees
13
Rev per Employee
$2.2m
Show more

Is XOMA Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,029 stocks worldwide.

XOMA Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a XOMA Corporation forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a XOMA Corporation forecast:

Buy
80%
Hold
20%

Financial data from XOMA Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
45 45
169% 169%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 31 31
18% 18%
69%
- Research and Development Expense 3.04 3.04
138% 138%
7%
11 11
149% 149%
24%
- Depreciation and Amortization 1.41 1.41
220% 220%
3%
EBIT (Operating Income) EBIT 9.54 9.54
142% 142%
21%
Net Profit -18 -18
42% 42%
-39%

In millions USD.

Don't miss a Thing! We will send you all news about XOMA Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

XOMA Corporation Stock News

Neutral
GlobeNewsWire
14 days ago
- Amendment includes finalized cash amount and updated CVR terms for tender offer - LAVA announces new date for extraordinary general meeting of shareholders EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Penn.
Negative
Seeking Alpha
28 days ago
XOMA Royalty Corporation preferred stocks offer diversification beyond mREITs and banks, but both XOMAO and XOMAP are now rated Sell. Recent high-cost financing and low tangible common equity raise risk concerns; both preferreds trade above par with limited call risk but high downside if called. XOMAP likely faces a call first, but both issues suffer from illiquidity, negative cash flow, and as...
Neutral
GlobeNewsWire
28 days ago
EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) and LAVA Therapeutics N.V.
More XOMA Corporation News

Company Profile

XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

Head office United States
CEO Owen Hughes
Employees 13
Founded 1981
Website xoma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today